Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating

Compass Therapeutics

19/02/2025 13:56

** Brokerage Piper Sandler initiates coverage on drug
developer Compass Therapeutics  CMPX.O  with an "overweight"
rating and a PT of $12 
    ** Brokerage says results from a mid-to-late stage trial,
for co's lead drug, tovecimig, could potentially help boost
shares
    ** Adds it will be a "win" if the drug shows more than 23%
effect on improving overall response rate, which is the
percentage of patients showing response to treatment
    ** Prior trial data for the drug when studied in combination
with a type of chemotherapy paclitaxel in biliary tract cancer
was promising 
    ** This suggests its mid-to-late stage trial results
(expected in March) should also report efficacy that will
support regulatory approval - Piper Sandler
    ** Estimates peak US sales of $635 million if approved as a
second line treatment for biliary tract cancer
    ** Co is also testing the drug in patients with colorectal
cancer
    ** Stock has risen 71.3% in the past 12 months 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))